JNCCN-360 - Ovarian

Editor:

Ursula A. Matulonis, MD

Advertisement

Advertisement

Ongoing CE Activities

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer

Expert Insights: Addressing Critical Questions in the Evolving Management of Ovarian Cancer (login required)

Consensus or Controversy: Management of initial relapse of ovarian cancer — Eight investigators weigh in on their current approach based on genomic profiling

Oncology Grand Rounds: PARP Inhibitors in Ovarian Cancer

Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Ovarian Cancer

Beyond the Guidelines: Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer

Selecting Cancer Treatment: The Role of Tumor Molecular Profiling and Liquid Biopsy

Second Opinion: New and Emerging Treatment Strategies in the Management of Recurrent Ovarian Cancer

The Emerging Role of Molecular Testing in an Era of Precision Medicine - Ovarian Cancer

Data + Perspectives: Biologic Basis and Available Clinical Research Underlying the Protocol and Nonresearch Use of PARP Inhibition in Patients with Ovarian and Breast Cancer

Year in Review: Proceedings from the Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

Sections

NCCN Resources

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.